HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 2,450.00
+20.00 (0.82%)
Jun 12, 2026, 3:30 PM KST
HLB Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -9,090 | -9,227 | -22,793 | -2,302 | -11,354 | -17,197 |
Depreciation & Amortization | 3,429 | 4,622 | 8,092 | 8,479 | 1,666 | 1,701 |
Loss (Gain) From Sale of Assets | -245.69 | -234.25 | 17.69 | -4.04 | 598.18 | 14.8 |
Asset Writedown & Restructuring Costs | 22.72 | 22.72 | 8,037 | 131.7 | 424.08 | 4,632 |
Loss (Gain) From Sale of Investments | -3,268 | -3,016 | 11,678 | -9,898 | 4.14 | 10.25 |
Loss (Gain) on Equity Investments | 7,252 | 7,594 | 433.03 | 1,406 | -1,883 | 349.23 |
Stock-Based Compensation | 512.1 | 602.55 | 813.12 | 213.52 | -83.89 | 153.28 |
Provision & Write-off of Bad Debts | 475.81 | 573.52 | 342.66 | -277.22 | -543.03 | -301.32 |
Other Operating Activities | -274.01 | 1,826 | -3,475 | 1,496 | 5,645 | 470.42 |
Change in Accounts Receivable | -5,156 | -4,590 | 762.96 | -1,135 | 1,355 | -1,659 |
Change in Inventory | -1,552 | -2,085 | 773.08 | 1,356 | -2,910 | 891.62 |
Change in Accounts Payable | 1,369 | 543.55 | -3,366 | 951.82 | 605.91 | -1,605 |
Change in Other Net Operating Assets | -129.26 | -4,810 | -28.79 | 2,909 | -2,332 | 1,273 |
Operating Cash Flow | -6,653 | -8,178 | 1,288 | 3,327 | -8,809 | -11,268 |
Operating Cash Flow Growth | - | - | -61.29% | - | - | - |
Capital Expenditures | -1,188 | -1,285 | -636.97 | -301.76 | -3,396 | -822.87 |
Sale of Property, Plant & Equipment | -2.26 | 58.65 | 46.06 | 2,596 | 216.25 | 40.91 |
Cash Acquisitions | - | - | - | - | -3,008 | - |
Divestitures | - | - | - | 5,915 | - | - |
Sale (Purchase) of Intangibles | -7,132 | -8,781 | -8,099 | -5,458 | -2,192 | -3,110 |
Investment in Securities | 14,724 | 7,437 | -26,740 | -24,133 | -30,370 | 18,872 |
Other Investing Activities | 1,768 | 2,006 | -27.32 | 1,220 | -3,409 | -697.5 |
Investing Cash Flow | 8,170 | -563.61 | -35,457 | -20,160 | -41,930 | 14,353 |
Long-Term Debt Issued | - | 32,000 | 26,000 | - | - | 65,000 |
Total Debt Issued | 27,000 | 32,000 | 26,000 | - | - | 65,000 |
Short-Term Debt Repaid | - | - | - | -3,118 | -755 | - |
Long-Term Debt Repaid | - | -20,543 | -7,114 | -15,096 | -2,556 | -22,146 |
Total Debt Repaid | -19,500 | -20,543 | -7,114 | -18,214 | -3,311 | -22,146 |
Net Debt Issued (Repaid) | 7,500 | 11,457 | 18,886 | -18,214 | -3,311 | 42,854 |
Issuance of Common Stock | - | 40.23 | 10,160 | 13,018 | - | 40,000 |
Repurchase of Common Stock | -183.11 | -354.55 | -636.17 | -70.12 | - | - |
Other Financing Activities | -19.88 | -18.41 | -15.69 | -14.59 | -7.08 | -0 |
Financing Cash Flow | 7,297 | 11,124 | 28,394 | -5,281 | -3,318 | 82,854 |
Foreign Exchange Rate Adjustments | 215.86 | -5.41 | 0.3 | 1.6 | 4.98 | 3.85 |
Net Cash Flow | 9,029 | 2,377 | -5,775 | -22,112 | -54,052 | 85,943 |
Free Cash Flow | -7,841 | -9,463 | 650.79 | 3,025 | -12,204 | -12,091 |
Free Cash Flow Growth | - | - | -78.49% | - | - | - |
Free Cash Flow Margin | -11.61% | -13.60% | 1.19% | 5.75% | -28.78% | -27.74% |
Free Cash Flow Per Share | -88.81 | -107.42 | 7.71 | 36.99 | -170.82 | -187.61 |
Cash Interest Paid | 374.7 | 393.97 | 100 | - | -28.3 | 1,261 |
Cash Income Tax Paid | 480.58 | 12.22 | 174.67 | -33.08 | 127.17 | 40.68 |
Levered Free Cash Flow | -14,889 | -20,395 | -9,511 | 7,272 | -14,458 | -12,654 |
Unlevered Free Cash Flow | -14,527 | -19,198 | -8,283 | 7,967 | -11,241 | -11,929 |
Change in Working Capital | -5,468 | -10,942 | -1,859 | 4,082 | -3,282 | -1,099 |